Biologics In Focus - February 2025
Welcome to the February edition of Biologics in Focus, the monthly newsletter from Lonza Biologics.
This month, we explore strategies that accelerate the path to the clinic for innovative therapies, from our integrated DNA-to-IND solutions to mRNA encapsulation technologies. We also highlight cutting-edge collaborations in ADC development with Boehringer and Mitsubishi Tanabe, as well as the latest in biologics tech transfer. Don’t miss insights on prefilled syringes, upcoming events, and webinars. Dive in for expert perspectives that keep you ahead in the ever-evolving biologics landscape.
If you find our content enriching, consider sharing it with your network and joining our ever-expanding group of over 111K subscribers who receive our monthly updates.
Insights and Analysis
As a CDMO, we provide integrated and streamlined DNA-to-IND solutions to accelerate drug development. By leveraging our expertise and advanced technologies, we help customers bring innovative therapies to the clinic faster. Our approach reduces complexity, mitigates risks, and enhances efficiency. This article explores how our accelerated strategies optimize timelines and support a faster path to patients in need.
In our podcast episode "A View On mRNA Encapsulation", we delve into the critical role of lipid nanoparticles (LNPs) in mRNA-based therapeutics. We discuss how encapsulating mRNA within LNPs enhances delivery efficiency and stability, facilitating the development of next-generation vaccines and treatments. Listeners will gain insights into advanced encapsulation technologies and their impact on accelerating mRNA therapeutic development. This episode is essential for those interested in the latest advancements in mRNA delivery systems.
As a CDMO, we offer integrated ADC development services by combining Synaffix’s GlycoConnect? platform with our Ibex? Design program. This collaboration enables developers to optimize ADC candidates more efficiently, reducing risks and accelerating the transition from discovery to clinical manufacturing. This white paper presents how our integrated solutions streamline ADC design and production, supporting faster and more successful therapeutic development.
We evaluated alternative detergents for viral inactivation in protein purification to replace Triton X-100 (TX-100), which harms aquatic life. Using multi-criteria decision analysis, we screened 16 candidates, selecting four for further study. Two, C16-AO and C11/15-sEO9, proved viable.
Lonza in the Press
Explore the key considerations for a successful technology transfer of biologics' upstream processes. Discover key factors such as product complexity, lifecycle stages, and potential risks. The article offers strategies to ensure efficient transfers, emphasizing the importance of structured, modular approaches and collaboration to maintain product quality and reduce time-to-market in biologics manufacturing.
Synaffix signs licensing agreements with Boehringer Ingelheim and Mitsubishi Tanabe Pharma to advance antibody-drug conjugate (ADC) programs. These agreements come when ADC partnerships rapidly increase in the pharmaceutical industry, with ADCs gaining prominence in cancer research. In November 2024, Synaffix signed a licensing deal with BigHat Biosciences, focused on AI, providing access to Lonza's ADC offerings. Earlier, in January 2023, Synaffix entered a $2 billion licensing agreement with Amgen for an ADC program.
Discover a novel workflow to make sure you are confident about the functionality of prefilled syringes (PFS) and autoinjectors. Read about the outlined smart, data-driven approach to confidently formulate biotherapeutics for PFS, addressing challenges such as assessing the injection force required to expel the liquid from a PFS.
Upcoming Events
Upcoming Webinars
Wednesday, 19 March 2025. 11am EST | 5pm CET
Thank you for reading. Remember to subscribe so you never miss our monthly updates.
If you'd like to find out more about Lonza Biologics, you can visit our website or contact one of our team of experts.
Learning and Development Professional
1 周Appreciate the process optimization strategies aimed at reducing DNA to IND timelines. Great work!
Life Sciences Expertise| GCP certified| Pharmaceutical Sales & Promotion| Representative| Product manager| Pharmaceutical business development manager| Key account manager |Product development manager| Marketing manager
1 周Thank you for the update in "Biologics In Focus". The focus on integrated DNA-to-IND solutions is particularly relevant. It's great to see how Lonza’s approach helps to accelerate timelines, ultimately supporting faster patient access to innovative therapies. Looking forward to seeing more on this
Marketing Manager @ Next Tr?ber AG | Innovative Marketing Strategies | Trade-Marketing | Digital-Marketing
3 周Fascinating insights into how integrated solutions accelerate biologics development! Lonza’s approach to streamlining DNA-to-IND, ADC innovations, and sustainable bioprocessing reinforces its leadership in the industry. I appreciate how these advancements drive real-world impact, accelerating the delivery of therapies to patients ?
Emcee Sylvia
3 周Well done!! ????
Grow sustainable and profitable businesses through innovation and entrepreneurship
3 周It is the smile that warms my heart. ????